Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
14.98
Dollar change
+0.76
Percentage change
5.34
%
IndexRUT P/E- EPS (ttm)-2.20 Insider Own28.50% Shs Outstand54.67M Perf Week16.21%
Market Cap818.96M Forward P/E- EPS next Y-2.15 Insider Trans37.95% Shs Float39.08M Perf Month14.97%
Income-54.74M PEG- EPS next Q-0.78 Inst Own69.78% Short Float5.02% Perf Quarter223.54%
Sales0.00M P/S- EPS this Y37.02% Inst Trans13.30% Short Ratio2.59 Perf Half Y66.63%
Book/sh3.18 P/B4.71 EPS next Y3.61% ROA-34.90% Short Interest1.96M Perf Year17.03%
Cash/sh3.46 P/C4.33 EPS next 5Y- ROE-36.82% 52W Range4.26 - 15.65 Perf YTD95.05%
Dividend Est.- P/FCF- EPS past 5Y45.77% ROI-29.67% 52W High-4.31% Beta0.72
Dividend TTM- Quick Ratio20.41 Sales past 5Y0.00% Gross Margin- 52W Low251.64% ATR (14)1.08
Dividend Ex-Date- Current Ratio20.41 EPS Y/Y TTM39.59% Oper. Margin0.00% RSI (14)64.38 Volatility9.18% 8.32%
Employees42 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price20.86
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q27.58% Payout- Rel Volume1.13 Prev Close14.22
Sales Surprise- EPS Surprise-29.44% Sales Q/Q- EarningsNov 13 BMO Avg Volume757.22K Price14.98
SMA206.36% SMA5042.38% SMA20074.79% Trades Volume852,030 Change5.34%
Date Action Analyst Rating Change Price Target Change
Mar-28-23Initiated Evercore ISI Outperform $18
Feb-29-24 03:02AM
Feb-20-24 08:00AM
Feb-06-24 08:00AM
Feb-05-24 04:00PM
Jan-30-24 07:29PM
09:08AM Loading…
09:08AM
Dec-04-23 04:00PM
Nov-27-23 08:00AM
Nov-21-23 08:00AM
Nov-14-23 01:07PM
Nov-13-23 11:07AM
08:00AM
Nov-10-23 08:00AM
Nov-09-23 08:00AM
Nov-03-23 08:10AM
04:00PM Loading…
Nov-02-23 04:00PM
Oct-30-23 08:00AM
Oct-11-23 07:14PM
05:10PM
Oct-03-23 04:00PM
Sep-06-23 08:00AM
Aug-31-23 08:00AM
Aug-30-23 10:01AM
Aug-25-23 08:00AM
Aug-07-23 04:10PM
Aug-02-23 04:00PM
Jul-20-23 08:00AM
Jul-17-23 08:00AM
Jul-14-23 08:00AM
Jul-06-23 04:00PM
08:00AM Loading…
Jun-06-23 08:00AM
Jun-05-23 08:00AM
May-31-23 08:00AM
May-11-23 04:10PM
May-02-23 04:00PM
Apr-28-23 08:00AM
Apr-19-23 08:00AM
Apr-04-23 04:00PM
Mar-22-23 08:00AM
Mar-08-23 08:00AM
Mar-06-23 08:00AM
Mar-02-23 04:00PM
Feb-24-23 08:00AM
Feb-21-23 08:00AM
Feb-08-23 08:00AM
Feb-02-23 04:00PM
Dec-19-22 04:01PM
Dec-15-22 06:10AM
06:00AM
Dec-02-22 04:00PM
Nov-10-22 04:10PM
Nov-09-22 08:00AM
Nov-07-22 08:00AM
Nov-02-22 08:00AM
Sep-16-22 08:00AM
Sep-06-22 08:00AM
Sep-02-22 08:00AM
Aug-09-22 04:32PM
Aug-04-22 08:00AM
Aug-03-22 08:00AM
Aug-02-22 08:00AM
Jul-29-22 09:34AM
Jul-28-22 08:00AM
Jul-15-22 08:00AM
Jul-14-22 08:00AM
Jul-05-22 08:00AM
Jun-23-22 08:00AM
Jun-03-22 08:00AM
Jun-02-22 08:00AM
May-12-22 04:10PM
Apr-21-22 08:00AM
Apr-04-22 08:00AM
Mar-10-22 05:01PM
Mar-09-22 08:00AM
Feb-18-22 08:00AM
Nov-10-21 08:00AM
Nov-09-21 08:00AM
Nov-05-21 08:00AM
Oct-27-21 08:00AM
Oct-21-21 08:00AM
Oct-18-21 08:00AM
Oct-12-21 08:00AM
Oct-03-21 09:52PM
Sep-10-21 08:00AM
Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PERCEPTIVE ADVISORS LLCDirectorFeb 01Buy12.092,481,35029,999,5224,873,721Feb 05 05:02 PM
Morabito ChristopherChief Medical OfficerJan 29Option Exercise3.879,20035,6049,200Jan 30 05:03 PM
Morabito ChristopherChief Medical OfficerJan 29Sale11.159,200102,5520Jan 30 05:03 PM
Morabito ChristopherChief Medical OfficerJan 26Option Exercise3.878003,096800Jan 30 05:03 PM
Morabito ChristopherChief Medical OfficerJan 26Sale11.028008,8120Jan 30 05:03 PM
PERCEPTIVE ADVISORS LLCDirectorDec 21Buy6.20740,0004,588,0002,392,371Dec 22 02:51 PM
PERCEPTIVE ADVISORS LLCDirectorOct 16Buy6.511,074,6086,999,9971,652,371Oct 18 04:11 PM